Nutriband Inc.
$4.2
▲
0.83%
2026-04-21 08:30:00
www.nutriband.com
NCM: NTRB
Explore Nutriband Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$51.13 M
Current Price
$4.2
52W High / Low
$11.68 / $3.42
Stock P/E
—
Book Value
$0.62
Dividend Yield
—
ROCE
-103.12%
ROE
-1.36%
Face Value
—
EPS
$-3.05
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.93
Debt / Equity
3.42
Current Ratio
7.53
Quick Ratio
4.66
Forward P/E
-16.96
Price / Sales
20.84
Enterprise Value
$42.36 M
EV / EBITDA
-4.69
EV / Revenue
18.59
Rating
Strong Buy
Target Price
$15
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Annexon, Inc. | $6.43 | — | $1.05 B | — | -92.11% | -81.9% | $7.18 / $1.4 | $1.42 |
| 2. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
| 3. | Edesa Biotech, Inc. | $6.75 | — | $49.5 M | — | -57.24% | -96.39% | $9.37 / $0.72 | $0.56 |
| 4. | Aprea Therapeutics, Inc. | $0.98 | — | $11.45 M | — | -100.49% | -74.58% | $2.22 / $0.55 | $1.52 |
| 5. | Agios Pharmaceuticals, Inc. | $27.07 | — | $1.54 B | — | -38.86% | -30.2% | $46 / $22.24 | $20.41 |
| 6. | Seer, Inc. | $1.99 | — | $112.84 M | — | -27.82% | -25.08% | $2.41 / $1.65 | $4.61 |
| 7. | Harmony Biosciences Holdings, Inc. | $29.53 | 10.93 | $1.73 B | — | 20.45% | 20.75% | $40.87 / $25.52 | $15.07 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.35 M | 0.62 M | 0.67 M | 0.64 M | 0.65 M | — |
| Operating Profit | -3.88 M | -2 M | -1.41 M | -1.96 M | -1.43 M | — |
| Net Profit | -3.87 M | -2 M | -1.39 M | -5.52 M | -1.36 M | — |
| EPS in Rs | -0.32 | -0.16 | -0.11 | -0.45 | -0.11 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.14 M | 2.09 M | 2.08 M | 1.42 M |
| Operating Profit | -6.69 M | -4.87 M | -4.15 M | -3.93 M |
| Net Profit | -10.48 M | -5.49 M | -4.48 M | -6.18 M |
| EPS in Rs | -0.86 | -0.45 | -0.37 | -0.51 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.47 M | 7.52 M | 9.46 M | 12.74 M |
| Total Liabilities | 1.04 M | 1.08 M | 0.88 M | 0.88 M |
| Equity | 6.43 M | 6.44 M | 8.57 M | 11.86 M |
| Current Assets | 4.79 M | 1.02 M | 2.69 M | 5.47 M |
| Current Liabilities | 0.98 M | 1 M | 0.75 M | 0.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.63 M | -3.53 M | -2.99 M | -2.81 M |
| Investing CF | -0.09 M | -0.05 M | -0.08 M | -0.08 M |
| Financing CF | 8.54 M | 2.09 M | 0.16 M | 7.63 M |
| Free CF | -4.72 M | -3.58 M | -3.07 M | -2.89 M |
| Capex | -0.09 M | -0.05 M | -0.08 M | -0.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 2.6% | 0.27% | 46.23% | — |
| Earnings Growth % | -91.1% | -22.35% | 27.41% | — |
| Profit Margin % | -489.95% | -263.04% | -215.59% | -434.28% |
| Operating Margin % | -312.67% | -233.63% | -199.45% | -276.33% |
| Gross Margin % | 34.74% | 41.34% | 36.08% | 35.46% |
| EBITDA Margin % | -475.62% | -245.61% | -199.32% | -403.57% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-08-12 | 1:1.166 |